Glycoproteins

GenScript ProBio Enters into Agreement with SYNIMMUNE for Manufacturing of their Innovative Antibody Drug

Retrieved on: 
Monday, September 6, 2021

NANJING, China, Sept. 6, 2021 /PRNewswire/ --GenScript ProBio is delighted to announce the signing of a manufacturing service agreement for Synimmune's innovative FLYSYN antibody project for clinical Phase II production.

Key Points: 
  • NANJING, China, Sept. 6, 2021 /PRNewswire/ --GenScript ProBio is delighted to announce the signing of a manufacturing service agreement for Synimmune's innovative FLYSYN antibody project for clinical Phase II production.
  • "GenScript ProBio and SYNIMMUNE GmbH entered into collaboration on FLYSYN antibody project for technology transfer and manufacturing of drug substance and drug product for Clinical Phase II trials, it is our pleasure to support this innovative antibody project," said Dr. Brian Min, CEO of GenScript ProBio, "GenScript ProBio's GMP manufacturing center meets global regulatory requirements.
  • We are confident that GenScript ProBio will produce SYNIMMUNE's lead antibody drug product FLYSYN to all global quality GMP standards within the agreed upon timeline.
  • GenScript ProBio's innovative solutions for antibody drug development include antibody drug discovery, antibody engineering and antibody characterization.

IGM Biosciences Announces the Appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., as Chief Medical Officer

Retrieved on: 
Thursday, July 29, 2021

Dr. Takimoto will be responsible for global development of IGMs clinical pipeline of proprietary IgM antibodies.

Key Points: 
  • Dr. Takimoto will be responsible for global development of IGMs clinical pipeline of proprietary IgM antibodies.
  • We look forward to working with him and our clinical team in continuing to advance our growing clinical pipeline of IgM antibodies.
  • Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies.
  • Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies.

Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platforms

Retrieved on: 
Wednesday, July 28, 2021

"We selected Landing AI because of the company's unique data-centric approach that puts getting high-quality data at the heart of AI development.

Key Points: 
  • "We selected Landing AI because of the company's unique data-centric approach that puts getting high-quality data at the heart of AI development.
  • The OmniAb antibody discovery platform provides Ligand's biopharmaceutical industry partners access to the world's most advanced antibody repertoires and screening technologies to enable unparalleled discovery of next-generation therapeutics.
  • Ligand's OmniAb technology platform is a patent-protected technology stack used in the discovery of fully human mono- and bispecific therapeutic antibodies.
  • The company's flagship product is LandingLens, an enterprise MLOps platform that offers end-to-end workflow to build, iterate and operationalize AI powered visual inspection solutions.

Global WholeHealth Partners Corp.'s (OTC: GWHP) Antibody IgG/IgM and Antigen Tests That They Offer Are Capable of Detecting the DELTA B.1.617.2, United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) of COVID 19 SARS 2

Retrieved on: 
Monday, July 26, 2021

Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM and Antigen tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.

Key Points: 
  • Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM and Antigen tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.
  • The government is working with the diagnostics industry to ensure the gains in domestic manufacturing are not lost over time.
  • To conquer COVID and win this war, Global must keep up the research and development of tests.
  • Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID.

Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery

Retrieved on: 
Monday, July 26, 2021

The collaborative research project resulted from a technology agreement between the companies to pursue novel antibody targets through Twists antibody discovery and optimization together with MOLCUREs AI technology.

Key Points: 
  • The collaborative research project resulted from a technology agreement between the companies to pursue novel antibody targets through Twists antibody discovery and optimization together with MOLCUREs AI technology.
  • Our expectations that this would reinforce our partners therapeutic antibody pipelines and further strengthen our AI driven molecule design service were confirmed in this project.
  • Twist Bioscience continues to innovate and incorporate the most advanced methods of antibody discovery and optimization into our processes, said Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • MOLCUREs AI approach complements our proprietary antibody discovery and optimization efforts, leveraging technology to refine our internal antibody pipeline.

Global WholeHealth Partners Corp (OTC:GWHP) Receives a Second Order for 10,000 Tests From Salud Previa of Tijuana, MX; Salud Previa has Ordered Over 30,000 Tests Now; Tests Sold Were Pregnancy Tests, Drug Tests, Dengue Fever, TB and COVID

Retrieved on: 
Tuesday, July 20, 2021

The Global WholeHealth Partners Corp (OTC:GWHP)COVID 19 Antigen and Antibody test can pick up the DELTA Variant.

Key Points: 
  • The Global WholeHealth Partners Corp (OTC:GWHP)COVID 19 Antigen and Antibody test can pick up the DELTA Variant.
  • Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest lines of COVID 19 tests.
  • Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.
  • Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID.

American Pharmacists Association Foundation, NOWDiagnostics Launch Nationwide In-Pharmacy Real-Time COVID-19 Antibody Testing with Spike Protein-Targeted, Rapid ADEXUSDx® Test

Retrieved on: 
Monday, July 19, 2021

The ADEXUSDx COVID-19 antibody test detects antibodies that bind to the receptor binding domain (RBD) subunit of the S1 spike protein of the SARS-CoV-2 virus.

Key Points: 
  • The ADEXUSDx COVID-19 antibody test detects antibodies that bind to the receptor binding domain (RBD) subunit of the S1 spike protein of the SARS-CoV-2 virus.
  • The most protective antibodies develop against this portion of the spike protein S1 domain and are induced by vaccination.
  • The APhA Foundation is affiliated with the American Pharmacists Association, the oldest and largest national professional society of pharmacists in the United States established in 1852.
  • The ADEXUSDxCOVID-19 Test will be distributed by C19 Development, LLC, a wholly owned subsidiary of NOWDiagnostics.

Global WholeHealth Partners Corp (OTC: GWHP), as Mentioned in the S1 Filing of July 2020, has Begun to Drawdown on the up to $100,000,000 in Equity Funding According to the Purchase Agreement with EMC2

Retrieved on: 
Monday, July 19, 2021

SAN CLEMENTE, CA, July 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire Global WholeHealth Partners Corp (OTC:GWHP) through this agreement is funded for growth and expansion.

Key Points: 
  • SAN CLEMENTE, CA, July 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire Global WholeHealth Partners Corp (OTC:GWHP) through this agreement is funded for growth and expansion.
  • The total amount of shares to be sold through the EMC2 agreement is up to 8,578,177 shares of common stock.
  • Global Wholehealth Partners Corp. (OTC:GWHP) provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

SQI Diagnostics and AZOVA sign distribution agreement to sell SQI's COVID-19 HOME Antibody Test

Retrieved on: 
Friday, July 16, 2021

SQI's data show that the test is >99% accurate and will be the first test of its kind for the consumer market.

Key Points: 
  • SQI's data show that the test is >99% accurate and will be the first test of its kind for the consumer market.
  • Consumers, employees and travelers will be able to purchase a test through AZOVA or from any of its retail partners.
  • "AZOVA is the ideal partner to distribute our revolutionary COVID-19 HOME Antibody Test.
  • "This test can be used to track antibody status over time for an individual or for an entire population.

Global Vectorized Antibodies for In Vivo Expression Market - by DNA and mRNA - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 13, 2021

Sales of recombinant therapeutic antibodies in the year 2020 exceeded US$ 184 bln (+11% vs previous year).

Key Points: 
  • Sales of recombinant therapeutic antibodies in the year 2020 exceeded US$ 184 bln (+11% vs previous year).
  • Manufacturing of recombinant antibodies requires large volumes, costly production and complex protein characterization.
  • Each of the three different approaches (AAV DNA, plasmid DNA and mRNA) for in vivo expression of antibodies has its specific profile of advantages and disadvantages.
  • This report evaluates the industry landscape of antibody vectorization with optimized technologies for direct in vivo delivery of synthetic nucleic acid-encoded antibodies.